An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC

Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adjuvant durvalumab Sponsors: ETOP IBCSG Partners Foundation; AstraZeneca AG Switzerland Not yet recruiting

https://clinicaltrials.gov/study/NCT06284317

Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials